Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ROS1 fusion |
| Therapy | ANS03 |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ROS1 fusion | lung non-small cell carcinoma | predicted - sensitive | ANS03 | Phase I | Actionable | In a Phase I trial, ANS03 treatment demonstrated manageable safety and preliminary efficacy in patients with non-small cell lung cancer harboring a ROS1 fusion, resulting in an objective response rate of 38.8% (7/18) in the overall cohort and 54.5% (6/11) in patients previously treated with at least 2 lines of previous systemic therapy including a prior ROS1 TKI (Cancer Res (2026) 86 (8_Supplement): CT061; NCT06716138). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Abstract CT061: A phase I study of the type II ROS1 TRK inhibitor ANS03 in ROS1 fusion-positive lung cancers | Full reference... |